Cue Biopharma (CUE) Change in Receivables (2019 - 2025)
Cue Biopharma (CUE) posted Change in Receivables of $5.2 million for Q4 2025, up 3657.93% sequentially from -$145000.0 in Q3 2025, and up 333.76% YoY from $1.2 million in Q4 2024.
Cue Biopharma (CUE) Change in Receivables (2019 - 2025) Analysis & Trends
Cue Biopharma has reported Change in Receivables for 7 years, with the latest figure at $5.2 million in Q4 2025.
- Quarterly Change in Receivables rose 333.76% year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 711.02% YoY) and the FY2025 annual result came in at $4.6 million, up 711.02% from the prior year.
- Change in Receivables improved to $5.2 million in Q4 2025 per CUE's latest filing, from -$145000.0 in the prior quarter.
- Over five years, Change in Receivables peaked at $5.2 million in Q4 2025 and troughed at -$2.2 million in Q1 2022.
- A 5-year average of $206452.2 and a median of $49000.0 in 2022 frame the typical range for Change in Receivables.
- The sharpest annual moves came in 2022 and 2023: Change in Receivables tumbled 55350.0% in 2022, then surged 776.67% in 2023.
- Over 5 years, Change in Receivables stood at $2.4 million in 2021, then tumbled by 131.13% to -$738000.0 in 2022, then jumped by 105.15% to $38000.0 in 2023, then sank by 5907.89% to -$2.2 million in 2024, then soared by 333.76% to $5.2 million in 2025.
- According to Business Quant data, Change in Receivables over the past three periods registered $5.2 million, -$145000.0, and $532000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -53.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 117.58 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 31.60 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 94.29 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 37.16 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.16 Mn |
| Dec 31, 2025 | 5.16 Mn |
| Sep 30, 2025 | -145,000.00 |
| Sep 30, 2025 | -145,000.00 |
| Jun 30, 2025 | 532,000.00 |
| Jun 30, 2025 | 532,000.00 |
| Mar 31, 2025 | -945,000.00 |
| Mar 31, 2025 | -945,000.00 |
| Dec 31, 2024 | -2.21 Mn |
| Dec 31, 2024 | -2.21 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Sep 30, 2024 | 1.31 Mn |
| Jun 30, 2024 | 447,000.00 |
| Jun 30, 2024 | 447,000.00 |
| Mar 31, 2024 | -298,000.00 |
| Mar 31, 2024 | -298,000.00 |
| Dec 31, 2023 | 38,000.00 |
| Dec 31, 2023 | 38,000.00 |
| Sep 30, 2023 | 526,000.00 |
| Sep 30, 2023 | 526,000.00 |